Yüklüyor......
Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
BACKGROUND: Vedolizumab was shown to be effective and safe for patients with ulcerative colitis (UC) or Crohn's disease (CD) in the GEMINI phase 3 and long‐term safety (LTS) studies. AIM: To report treatment persistence and safety results up to 2 years after enrolment in the vedolizumab extende...
Kaydedildi:
| Yayımlandı: | Aliment Pharmacol Ther |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7839669/ https://ncbi.nlm.nih.gov/pubmed/33210333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16160 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|